Status:
COMPLETED
Bevacizumab Treatment and Retinal Vessel Monitoring
Lead Sponsor:
Technische Universität Dresden
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
Detailed Description
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
Eligibility Criteria
Inclusion
- patients who wish and need bevacizumab treatment for underlying disease
Exclusion
- previous bevacizumab treatment
- known eye disease, eye surgery or eye trauma in history
- myopia \>-2.0 dpt
- hyperopia \> +2.0 dpt.
- relevant media opacity of the lens
- acute heart disease, ischemic insult, proven coronary heart disease
- cardiac arrhythmia or vessel anomalies
- seizure disorder or episode in history
- migraine
- treatment with corticosteroids within 4 weeks before study inclusion
- intake of vasoactive drugs like AT-1 or glitazone
- pregnancy
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00740168
Start Date
May 1 2007
End Date
April 1 2009
Last Update
January 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Autonomic lab (ANF)
Dresden, Saxony, Germany, 01307